BioInvent's BI-1808 Combined with KEYTRUDA® Induces Durable Responses in Platinum-Resistant Ovarian Cancer

BioInvent International announced updated data from its clinical study of BI-1808, a first-in-class anti-TNFR2 antibody, in combination with MSD's KEYTRUDA (pembrolizumab) for patients with advanced platinum-resistant recurrent ovarian cancer. The data, presented at the ESMO Congress 2026, showed durable responses in heavily pretreated patients, offering a potential new immunotherapy option.